Relay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder
Relay Therapeutics’ R&D chief remains convinced the biotech’s PI3Kα inhibitor will carve out its own niche after reporting a slice of phase 2 data in patients with a type of blood vessel disorder. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results